Brokerages Expect Erytech Pharma SA (ERYP) Will Post Earnings of -$0.50 Per Share
Equities research analysts forecast that Erytech Pharma SA (NASDAQ:ERYP) will announce earnings of ($0.50) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Erytech Pharma’s earnings. Erytech Pharma reported earnings of ($0.19) per share during the same quarter last year, which suggests a negative year over year growth rate of 163.2%. The business is scheduled to announce its next quarterly earnings report before the market opens on Tuesday, September 11th.
On average, analysts expect that Erytech Pharma will report full year earnings of ($2.42) per share for the current fiscal year, with EPS estimates ranging from ($2.66) to ($2.17). For the next financial year, analysts anticipate that the firm will report earnings of ($2.93) per share, with EPS estimates ranging from ($3.41) to ($2.44). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Erytech Pharma.
ERYP has been the subject of several recent research reports. Zacks Investment Research raised shares of Erytech Pharma from a “sell” rating to a “hold” rating in a report on Monday, August 27th. Cowen reissued a “buy” rating on shares of Erytech Pharma in a report on Monday, June 25th.
Shares of Erytech Pharma stock traded down $0.16 during trading on Monday, hitting $9.64. 890 shares of the company’s stock were exchanged, compared to its average volume of 624. The company has a debt-to-equity ratio of 0.01, a current ratio of 16.52 and a quick ratio of 16.50. Erytech Pharma has a 52-week low of $9.64 and a 52-week high of $30.56. The stock has a market cap of $175.76 million and a PE ratio of -2.89.
Erytech Pharma Company Profile
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Recommended Story: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.